METABOLOMIC BIOMARKERS AS PREDICTORS OF CARDIOVASCULAR RISK IN PATIENTS WITH SYSTEMIC LUPUS ERYTHESUM
Systemic Lupus Erythemitas; cardiovascular risk; metabolomics
INTRODUCTION: Systemic Lupus Erytheamus is a chronic, immunomediated inflammatory disease, where the loss of immune regulation and the presence of autoantibodies result in multiple organ involvement. Lupus patients have increased cardiovascular risk compared to healthy people of the same sex and age. Existing methods of cardiovascular risk screening are not sufficient for patients with Systemic Lupus Erytheamus. OBJECTIVES: To evaluate metabolomic biomarkers that may be predictors and aid for cardiovascular risk assessment in this population. MATERIALS AND METHODS: Observational study and cross-sectional cohort. The sample was selected by convenience, composed of patients with SLE by the Rheumatology outpatient clinic of the Professor Alberto Antunes Hospital, a tertiary hospital in a northeastern capital. Patients of both sexes over the age of 18 years were included and signed the Free Consent and Informed Consent Form (Informed Consent). For the comparative analysis, the sample of patients control by convenience was also selected, composed of people of both sexes aged over 18 years who did not have autoimmune disease. These control patients also signed the Free Consent and Informed Consent Term (TCLE). Blood examination was collected at the Laboratory of the Professor Alberto Antunes University Hospital and a sample was sent to the Chemistry Laboratory of the Federal University of Alagoas for metabolomics evaluation. Subsequently, a statistical comparison of patients with Lupus and controls will be performed.